Pfizer's (PFE) and Bristol-Myers Squibb's (BMY) Eliquis blood thinner cut the risk of clots in...

Pfizer's (PFE) and Bristol-Myers Squibb's (BMY) Eliquis blood thinner cut the risk of clots in veins and lungs, and death, by 81% compared with a placebo in major year-long trial. Bleeding was also low. BMY could rack up sales of $4.18B by 2018 if Eliquis is approved - the drug would compete with warfarin, Xarelto from Bayer and J&J (JNJ), and Pradaxa from Boehringer Ingelheim. (PR)

From other sites
Comments (5)
  • blueice
    , contributor
    Comments (4179) | Send Message
    So the committee of ten, needs another six years while thousands die...


    Thank you, FDA...
    9 Dec 2012, 01:27 PM Reply Like
  • Hellz
    , contributor
    Comments (173) | Send Message
    It's not like it's the only blood thinner drug
    9 Dec 2012, 04:46 PM Reply Like
  • blueice
    , contributor
    Comments (4179) | Send Message
    HELLZ, any drug that has an efficacy of 81% is considered by many as a miracle drug...


    Of course, the FDA approval prodigal is so archaic, that in the process thousand of patients die awaiting their anointment...


    For the sake of saving a few, they kill hundreds or thousands...


    Government at its best, Hellz...
    9 Dec 2012, 05:27 PM Reply Like
    , contributor
    Comment (1) | Send Message
    Note the efficacy is against placebo, NOT any of the other methods of anticoagulation (blood thinning) -- this is essentially a worthless study.
    Yes, treatment (thinning blood in at risk patients) is better than no treatement -- DUH!!
    Until there are head to head trials with Warfarin (coumadin) or the other anticooagulants (Pradexa, Xarelto, aprixiban, etc.) this study is close to meaningless, and at best a Phase I study demonstrating "proof of concept" equivalent.


    Also suspect this study was not done in US or EU, since no IRB would approve the placebo arm of the study in "at-risk" patients.
    9 Dec 2012, 08:32 PM Reply Like
  • blueice
    , contributor
    Comments (4179) | Send Message
    See page two, Reichman...It is standard FDA operating procedure..


    But you are correct that it is simply stage one of testing and I gave it too much credit...

    10 Dec 2012, 02:17 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs